Galapagos NV (NASDAQ:GLPG) Short Interest Update

Galapagos NV (NASDAQ:GLPG - Get Free Report) was the target of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 1,710,000 shares, an increase of 8.2% from the January 15th total of 1,580,000 shares. Based on an average daily trading volume, of 266,400 shares, the days-to-cover ratio is currently 6.4 days. Currently, 2.7% of the company's stock are sold short.

Galapagos Stock Up 0.0 %

GLPG traded up $0.01 on Friday, hitting $26.74. The company had a trading volume of 286,483 shares, compared to its average volume of 328,102. The company's fifty day moving average price is $25.42 and its 200 day moving average price is $27.06. Galapagos has a 1-year low of $22.36 and a 1-year high of $39.91.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. R Squared Ltd bought a new position in Galapagos in the 4th quarter worth approximately $26,000. GAMMA Investing LLC increased its position in Galapagos by 140.7% in the 3rd quarter. GAMMA Investing LLC now owns 1,259 shares of the biotechnology company's stock worth $36,000 after buying an additional 736 shares during the period. China Universal Asset Management Co. Ltd. increased its position in Galapagos by 63.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,899 shares of the biotechnology company's stock worth $112,000 after buying an additional 1,510 shares during the period. Signaturefd LLC increased its position in Galapagos by 65.6% in the 3rd quarter. Signaturefd LLC now owns 6,413 shares of the biotechnology company's stock worth $185,000 after buying an additional 2,541 shares during the period. Finally, QRG Capital Management Inc. bought a new position in Galapagos in the 3rd quarter worth approximately $247,000. 32.46% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on GLPG. Kepler Capital Markets lowered Galapagos from a "hold" rating to a "reduce" rating in a report on Wednesday, November 20th. Royal Bank of Canada reduced their price target on Galapagos from $32.00 to $30.00 and set a "sector perform" rating for the company in a report on Friday, November 1st. Barclays reiterated an "underweight" rating on shares of Galapagos in a report on Thursday, January 23rd. Morgan Stanley lowered Galapagos from an "equal weight" rating to an "underweight" rating and reduced their price target for the company from $31.00 to $22.00 in a report on Friday, February 14th. Finally, TD Cowen lowered Galapagos from a "strong-buy" rating to a "strong sell" rating in a report on Thursday, January 9th. Five analysts have rated the stock with a sell rating and five have issued a hold rating to the company's stock. According to data from MarketBeat, Galapagos currently has an average rating of "Hold" and a consensus target price of $26.75.

About Galapagos

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.